EC approves Vertex’s Orkambi for cystic fibrosis in children
The EC approved extending the label for Vertex Pharmaceuticals’ Orkambi to treat cystic fibrosis in children aged one to two years.
The EC approved extending the label for Vertex Pharmaceuticals’ Orkambi to treat cystic fibrosis in children aged one to two years.
What's Your Reaction?
